Cowen & Co. Sticks to Their Buy Rating for MacroGenics (MGNX)


Cowen & Co. analyst Boris Peaker maintained a Buy rating on MacroGenics (MGNX) today. The company’s shares opened today at $20.65.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.6% and a 44.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MacroGenics with a $36 average price target, representing a 74.3% upside. In a report issued on February 20, H.C. Wainwright also maintained a Buy rating on the stock with a $39 price target.

See today’s analyst top recommended stocks >>

Based on MacroGenics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $44.64 million. In comparison, last year the company had a net profit of $106 million.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MGNX in relation to earlier this year. Last month, Eric Blasius Risser, the Sr VP & Chief Business Officer of MGNX bought 6,000 shares for a total of $5,640.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab.

Read More on MGNX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts